Corautus Genetics Inc. Conference Call on Boston Scientific and Corautus Genetics Alliance.

Business Editors/Health/Medical Writers

SAN DIEGO--(BUSINESS WIRE)--July 30, 2003

- Call Scheduled for Thursday, July 31, 2003 at 10:00 a.m. EDT -

Corautus Genetics Inc. (AMEX: CAQ) has scheduled a conference call to discuss the recently announced alliance with Boston Scientific Corporation to develop and commercialize cardiovascular and vascular therapies using the vascular growth factor gene 2, also known as VEGF-2. The call is scheduled for July 31, 2003, at 10:00 a.m. EDT.

To participate, please call the following numbers:

 --  From the U.S. and Canada: 1-800-838-4403

 --  International: 1-973-317-5319

Participants are asked to call the above numbers 5-10 minutes prior to the starting time.

A telephone replay of this call will be available from 12:00 p.m. on July 31, 2003 through 11:59 p.m. on August 5, 2003. Please call 1-800-428-6051 (domestic) or 973-709-2089 (international) and use the access number 302219.

For more information, call: Lisa Lindberg or Dian Griesel at The Investor Relations Group. Phone: [phone].

About Corautus Genetics

Corautus Genetics Inc. is a biopharmaceutical company dedicated to the development of innovative gene therapy products for the treatment of cardiovascular disease. Corautus Genetics was formed by the merger of Vascular Genetics Inc. with GenStar Therapeutics Corporation to capitalize on the complementary strengths of these companies to accelerate the development of a later stage product for cardiovascular disease. Corautus Genetics's core technology is based upon gene therapy for "therapeutic angiogenesis." In this approach, the injection of genes for vascular growth factors stimulate the formation of new blood vessels to help compensate for reduced blood flow due to advanced cardiovascular disease. The focus of the company's efforts will be the clinical development of gene therapy products using a vascular growth factor gene (Vascular Endothelial Growth Factor 2 or "VEGF-2") for the treatment of severe cardiovascular disease.

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements which address operating performance, events or developments that we expect or anticipate will occur in the future, such as projections about our future results of operations or our financial condition, benefits from the alliance with Boston Scientific, synergies from the merger between GenStar and Vascular Genetics, research, development and commercialization of our product candidates, anticipated trends in our business, approval of our product candidates and other risks that could cause actual results to differ materially. These risks are discussed in Corautus Genetics Inc.'s Securities and Exchange Commission filings, including, but not limited to, the risks discussed in Corautus' Annual Report on Form 10-K (File No. 001-15833) filed March 28, 2003, which are incorporated by reference into this press release.